Aeolus Pharmaceuticals, Inc.
AOLS
$0.0001
$0.000.00%
| 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | 06/30/2016 | |
|---|---|---|---|---|---|
| Revenue | -68.71% | -24.05% | -25.57% | -33.27% | -46.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.71% | -24.05% | -25.57% | -33.27% | -46.36% |
| Cost of Revenue | -13.08% | 33.11% | -4.95% | -17.90% | -40.22% |
| Gross Profit | -327.05% | -325.48% | -90.69% | -102.26% | -99.50% |
| SG&A Expenses | 4.17% | 10.59% | 20.94% | 10.73% | -9.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.44% | 21.86% | 5.77% | -6.78% | -29.66% |
| Operating Income | -52.70% | -54.92% | -34.94% | -24.60% | 1.43% |
| Income Before Tax | -37.94% | -39.48% | -21.87% | -35.35% | -9.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.94% | -39.48% | -21.87% | -35.35% | -9.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.94% | -39.48% | -21.87% | -35.35% | -9.16% |
| EBIT | -52.70% | -54.92% | -34.94% | -24.60% | 1.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.15% | 29.22% | -40.70% | -111.40% | -86.50% |
| Normalized Basic EPS | -32.03% | -29.69% | -10.37% | -23.97% | -2.40% |
| EPS Diluted | 10.71% | 10.71% | -43.68% | -55.42% | -32.15% |
| Normalized Diluted EPS | -32.03% | -29.69% | -10.37% | -23.97% | -2.40% |
| Average Basic Shares Outstanding | 5.15% | 8.01% | 11.02% | 9.43% | 6.63% |
| Average Diluted Shares Outstanding | 5.15% | 8.01% | 11.02% | 9.43% | 6.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
